[
  {
    "ts": "2025-10-25T20:10:19+00:00",
    "headline": "How the Story for AbbVie Is Evolving After Key Pipeline Wins and Analyst Shifts",
    "summary": "AbbVie stock has seen its consensus analyst price target rise modestly from $232.78 to $237.48 per share. This change reflects evolving views in the wake of recent company updates. The shift is largely driven by extended product exclusivity and changing analyst sentiment tied to both opportunities and risks across AbbVie’s portfolio. Read on to learn how investors can keep pace with the latest shifts in AbbVie's narrative and stay informed about future developments. What Wall Street Has Been...",
    "url": "https://finance.yahoo.com/news/story-abbvie-evolving-key-pipeline-201019893.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "a99cb697-2c44-31d4-b56a-0747d541379f",
      "content": {
        "id": "a99cb697-2c44-31d4-b56a-0747d541379f",
        "contentType": "STORY",
        "title": "How the Story for AbbVie Is Evolving After Key Pipeline Wins and Analyst Shifts",
        "description": "",
        "summary": "AbbVie stock has seen its consensus analyst price target rise modestly from $232.78 to $237.48 per share. This change reflects evolving views in the wake of recent company updates. The shift is largely driven by extended product exclusivity and changing analyst sentiment tied to both opportunities and risks across AbbVie’s portfolio. Read on to learn how investors can keep pace with the latest shifts in AbbVie's narrative and stay informed about future developments. What Wall Street Has Been...",
        "pubDate": "2025-10-25T20:10:19Z",
        "displayTime": "2025-10-25T20:10:19Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/4451284b0632c6e74466a63400764edd",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/cbaG7tZ9A8mqrilci3AeIQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4451284b0632c6e74466a63400764edd.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/1OA9tdPdimVe1Dv1fa4MAQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/4451284b0632c6e74466a63400764edd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/story-abbvie-evolving-key-pipeline-201019893.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/story-abbvie-evolving-key-pipeline-201019893.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]